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There has been the need to make major modifications to the 
way cardiology is practised in light of the COVID-19 pandemic. 
There has also been the need to recognise the complex 
cardiovascular manifestations and complications of COVID-19. 
In this article we provide guidance on the management of 
cardiac patients without COVID-19 in the current pandemic 
as well as patients with cardiac disease and COVID-19 and 
patients with cardiac complications of COVID-19. There is 
also a focus on indications and interpretation of commonly 
performed cardiac investigations in the setting of COVID-19. 
References are included from a number of specialist societies 
and groups.




The UK is affected by the novel coronavirus disease 2019 
(COVID-19) due to the global spread of the severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2).
We will discuss in this article relevant advice in four situations 
that the practicing physician may face in relation to COVID-19 and 
cardiovascular disease (CVD) in the current pandemic:
 > the patient without COVID-19 but with CVD
 > differentiating COVID-19 symptoms from a presentation of CVD
 > the patient with COVID-19 and pre-existing CVD
 > the patient with COVID-19 who has developed cardiovascular 
complications. 
A summary is provided in Box 1.
The present article is based on recommendation and guidelines 
from NHS England and the relevant British cardiac societies, 
including the British Cardiovascular Society (BCS), British 
Cardiovascular Interventional Society (BCIS), British Heart Rhythm 
Society (BHRS), Association for Inherited Cardiac Conditions, 
British Society of Heart Failure (BSH) and British Society of 
Echocardiography (BSE). Clinicians, however, are advised to refer to 
their local hospital/trust policies in the first instance.
The patient without COVID-19 but with 
cardiovascular disease
The management of these patients is aimed towards limitation 
of face-to-face contact and avoidance of non-urgent procedures. 
To this end, patients booked into outpatient clinics and on elective 
waiting lists will be reviewed by the relevant consultant cardiologist. 
Where possible, outpatient clinics are being conducted virtually, 
with only essential face-to-face appointments being carried out. 
Similarly, new referrals are triaged, and patients seen or deferred 
according to clinical urgency. Unless otherwise directed, referrals to 
outpatient services should continue; however, clinicians should be 
aware that appointments may be delayed and the availability of 
cardiac diagnostics services may be limited. All patients on elective 
waiting lists will be triaged and their procedures arranged/deferred 
as appropriate. In most cardiac tertiary centres, the capacity for 
cardiac procedures will be significantly reduced, with most centres 
offering urgent coronary intervention and pacing.
Acute coronary syndrome and out-of-hospital  
cardiac arrest
Primary percutaneous coronary intervention (PCI) remains the gold 
standard of care for patients with ST-elevation myocardial infarction 
(STEMI). 
In non-ST-elevation MI (NSTEMI), coronary angiography may 
still be considered, particularly in the presence of high-risk features 
(ie troponin elevation >5 times upper limit of normal, dynamic 
electrocardiography changes, unstable symptoms despite treatment, 
haemodynamic instability, shockable cardiac arrest). Patients with 
NSTEMI or unstable angina without high risk features (eg small 
troponin rise, no ECG changes) or where disruptions to transport 
services results in significant delays in interhospital transfer (>5 days) 
may be treated with optimal medical management and coronary 
angiography deferred as an outpatient.1 
For out-of-hospital cardiac arrest, only patients with clear ST 
elevation and no significant co-morbidities or other features suggesting 
a poor outcome should be transferred to a primary PCI centre.
Arrhythmia services
For patients with arrhythmias, clinical guidelines by NHS England,1 
with input and endorsement of BCS and BHRS, recommend that 
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Box 1. Summary of advice relating to cardiovascular disease management during COVID-19
Patients without COVID-19 but with cardiovascular disease
Services are being restructured to limit face-to-face contact and avoid non-urgent procedures
Virtual clinics will replace outpatients and only essential face-to-face appointments will continue
Elective cardiac procedures will be deferred or scheduled based on urgency
Referrals to outpatient services should continue, although appointments may be delayed
Coronary angiography in ACS will be performed or delayed according to clinical urgency (eg primary PCI performed in STEMI, delayed in 
NSTEMI with low risk features)
Optimisation of medications is key in ACS
PCI may be preferred over cardiac surgery in high-risk ACS with multivessel disease
Acute pacing will be available in most centres but reserved for high risk (eg high-grade AVB, severe symptomatic SND and long pauses)
Defibrillators (+/– CRT) will be reserved for secondary prevention (eg SCD survivors, ventricular arrhythmias with haemodynamic compromise)
Remote device checks and monitoring will be utilised where possible
Only urgent catheter ablations will be carried out (eg VT ablation in VT storm, pre-excited AF in WPW, atrial arrhythmias causing heart failure)
ACEi/ARBs should not be discontinued due to COVID-19 concerns
BNP testing in suspected heart failure can help prioritise patients needing urgent assessment
Differentiating COVID-19 symptoms from a presentation of CVD
Recognise that there is an overlap in clinical features of COVID-19 and cardiac diseases
Avoid (if possible) auscultation of the chest in patients with symptoms suggestive of COVID-19
Recognise that Brugada syndrome may be unmasked by fever in COVID-19, and although this is a rare condition there are important 
implications for management
The patient with COVID-19 and pre-existing CVD
There is a high prevalence of CVD in COVID-19 patients
CVD is associated with worse outcomes (ie increased need for intensive care, higher mortality)
The patient with COVID-19 who has developed cardiovascular complications
Heart failure is a common finding in patients with COVID-19, and carries a worse prognosis
Left ventricular systolic dysfunction may be pre-existing, or a result of COVID-19-induced myocarditis, or of inflammatory-mediated 
cardiomyopathy
Patients with left ventricular systolic dysfunction are at higher risk of needing mechanical ventilation
Elevated serum troponin and BNP confers a worse prognosis
Primary PCI remains the gold standard of care for STEMI in patients with COVID-19 but thrombolysis can be considered in selected cases
TTE can be considered in patients with COVID-19 but TOE should be avoided 
Arrhythmias are common in COVID-19
PPM is generally deferred, but in unstable cases temporary pacing can be considered
Emerging drugs (eg lopinavir, hydroxychloroquine) carry pro-arrhythmia risks and may necessitate monitoring  
ACEi = angiotensin converting enzyme inhibitor, ACS = acute coronary syndrome, AF = atrial fibrillation, ARB = angiotensin receptor blocker, AVB = 
atrioventricular block, BNP = brain natriuretic peptide, CRT = cardiac resynchronisation therapy, CVD = cardiovascular disease, NSTEMI = non ST elevation 
myocardial infarction, PCI = percutaneous coronary intervention, PPM = permanent pacemaker, SCD = sudden cardiac death, SND = sinus node dysfunction, 
STEMI = ST elevation myocardial infarction, TTE = transthoracic echocardiography, TOE = transoesophageal echocardiography, VT = ventricular tachycardia.
patients with uncontrolled atrial fibrillation (AF) or ventricular 
tachycardia (VT) will require hospital admission but all elective 
admissions should be deferred. Urgent pacemaker implantations 
should continue in patients with symptomatic complete heart 
block, Mobitz II atrioventricular (AV) block, high grade AV block 
with symptoms or severe symptomatic sinus node dysfunction with 
long pauses. Most elective pacemaker generator replacements can 
be postponed but urgent procedures should continue, especially 
in pacemaker-dependent patients without underlying rhythm 
and end of life battery status. Similarly, with regard to complex 
pacing (defibrillators, cardiac resynchronisation therapy), only 
urgent implants will be carried out, for example for secondary 
prevention of sudden cardiac death in cardiac arrest survivors 
or in patients with VT associated with syncope. Remote follow-
up and monitoring of devices should be considered in patients 
if this is not already enabled and will be led by local hospital 
protocols. Invasive treatment with ablation should continue for 
emergency life-threatening tachy-arrhythmias like AF rapidly 
conducted via accessory pathway in patients with Wolff-Parkinson-
White syndrome, VT storm resistant to pharmacotherapy in a 
haemodynamically compromised patient, and any other incessant 
arrythmias (supraventricular tachycardia, AF, atrial flutter) refractory 
to medical management or associated with significant left 
ventricular systolic dysfunction and heart failure. 
Angiotensin-converting enzyme inhibitors
It has been shown that the SARS-CoV-2 interacts with the 
renin-angiotensin-aldosterone system (RAAS) through 
angiotensin-converting enzyme 2 (ACE2), which is an enzyme 
that physiologically decreases RAAS activation. It also acts as a 
receptor for the SARS-CoV-2 virus.2 Concerns have been expressed 
regarding the role of ACE inhibitors and angiotensin receptor 
blockers (ARBs) in COVID-19, based on the finding that they may 
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increase expression of ACE2. Vaduganathan et al3 have discussed 
the complex area of renin-angiotensin-aldosterone-system (RAAS) 
inhibition in the setting of COVID-19 and propose an alternative 
hypothesis suggesting that RAAS blockade may be beneficial 
rather than harmful in patients with lung injury. The BCS and 
other specialist societies have recommended that patients (eg 
those with hypertension, heart failure or prior MI) should continue 
their ACE and ARB inhibitors unless directly advised to stop by a 
medical practitioner, due to the risk of decompensation following 
discontinuation of ACE/ARB inhibitors.4
Heart failure services
The BCS has also issued email guidance regarding prioritisation of 
heart failure service provision during COVID-19 aimed at reducing 
face-to-face contact and assessing those with greatest clinical 
need according to NICE guidance,5 which recommends the urgent 
referral of people with suspected heart failure and an NT-proBNP 
level above 2,000 ng/litre for specialist assessment and transthoracic 
echocardiography within 2 weeks. There will, however, be challenges 
in obtaining serum BNP levels in the community, as community 
phlebotomy services are affected and most general practices have 
switched to telephone appointments. 
The patient with COVID-19 symptoms who has 
cardiovascular disease
The presence of this pandemic and its serious consequences for 
patients and healthcare staff makes this condition foremost in 
our minds at the current time. The clinical presentation is quite 
variable, with Guan et al6 showing presentations of fever (88.7%), 
cough (67.8%), fatigue (38.1%), sputum production (33.4%) and 
shortness of breath (18.6%) in their Chinese study. Auscultation of 
the chest should be undertaken with appropriate personal protective 
equipment (PPE) and where possible the patient should wear a 
mask to reduce the risk of transmission. The stethoscope should be 
thoroughly cleaned using appropriate alcohol-based disinfectants. 
We must be aware of the diagnostic problems associated with 
cognitive bias that could potentially occur and thus miss other 
conditions. A case from our unit is briefly presented in this regard.
A 75-year-old man with a history of angina, hypertension and 
chronic obstructive pulmonary disease (COPD) presented with 
worsening shortness of breath. He was febrile, lethargic, confused 
and vacant with a respiratory rate of 40, crackles and a systolic 
murmur. He was treated for an infective exacerbation of COPD and 
suspected COVID-19. He received antibiotics, steroids, diuretics 
and non-invasive ventilation. COVID-19 swab was negative. 
Transthoracic echocardiography showed the presence of critical 
aortic stenosis for which he underwent aortic valve replacement.
The patient with COVID-19 and pre-existing 
cardiovascular disease
Li et al7 in their meta-analysis of six studies inclusive of 1,527 
COVID-19 patients reported the prevalence of hypertension 
and CVD to be 17.1% and 16.4%, respectively. It has also been 
suggested that there is a higher risk for adverse events in patients 
with CVD who contract COVID-19. Case-fatality rates in an analysis 
of 44,672 confirmed COVID-19 cases from Wuhan, China were 
noted to be 10.5% in patients with CVD and 6% in patients with 
hypertension, all notably higher than the overall case-fatality rate 
of 2.3%.8 Physicians managing these patients need to be aware of 
the likelihood of more severe forms of illness, greater intensive care 
requirement and worse outcomes.
Fig 1. Brugada syndrome may be unmasked by fever in COVID-19.
Brugada syndrome, a rare inherited cardiac condition 
(channelopathy) associated with increased risk of sudden death, may 
be unmasked by fever associated with COVID-19.9 Clinicians should 
recognise the characteristic ECG pattern (Fig 1), as the diagnosis has 
implications for immediate and future management, with patients
requiring prompt treatment of fever, consideration of hospital 
admission and cardiac monitoring, and avoidance of the 
contraindicated drugs listed on www.brugada.org. The Association 
for Inherited Cardiac Conditions has provided guidance for patients 
with Brugada syndrome and other inherited cardiac conditions 
including long QT syndrome, dilated cardiomyopathy, arrhythmogenic 
cardiomyopathy and hypertrophic cardiomyopathy.10
The patient with COVID-19 and cardiovascular 
complications
Heart failure
Zhou et al11 reported that 23% of patients with confirmed 
COVID-19 infection had evidence of heart failure. Patients with 
heart failure were also less likely to survive hospitalisation compared 
to those that did not (51.9% vs 11.7%). It is worth noting that in 
this series, it is unclear whether the heart failure observed was an 
exacerbation of pre-existing left ventricular systolic dysfunction, 
a new cardiomyopathy secondary to myocarditis, a cytokine-
induced cardiomyopathy or a combination of these factors. 
Unproven strategies for cytokine storm include steroids, intravenous 
immunoglobulin and selective cytokine blockade drugs. There is a 
higher likelihood of the need for mechanical ventilation in those 
patients with systolic impairment and reduced ejection fraction.12 
Treatment is as standard but advanced circulatory support is unlikely 
to be given due to uncertainty regarding prognosis. 
Arrhythmias
Cardiac arrhythmias are common in patients with COVID-19. In the 
report from Wuhan, China, arrhythmias occurred in 16.7% of 
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hospitalized and 44.4% of ICU patients, although they did not 
specify which arrhythmias.13 Extensive inflammatory reaction plays a 
major role as it may directly affect the electrical system of the heart 
or facilitate arrhythmias secondary to myocarditis, heart failure and 
acute coronary syndrome.14 In patients with confirmed COVID-19 
infection with an indication for permanent pacing, implantation 
is generally postponed until infection is cured. In unstable cases, a 
temporary externalised pacing system or a permanent pacemaker 
can be considered in a dedicated ‘hot’ theatre for COVID-19 
patients following individual assessment of risks versus benefits. 
In the setting of cardiac arrest, the gold standard is full aerosol-
generating procedures PPE, but a risk assessment can be done to 
decide on the level of protection. The Resuscitation Council UK has 
provided guidance for resuscitation in health care settings.15
Cardiac biomarkers (high-sensitivity troponin and  
BNP/NT-proBNP)
Detectable high-sensitivity troponin-I (hs-cTnI) has been observed in 
most patients with COVID-19 and was significantly elevated in more 
than half of the patients that died.11 A rise and/or fall of hs-cTn is 
insufficient to make a diagnosis of acute myocardial infarction (MI). 
The American College of Cardiology recommends only measuring 
troponin if there is clinical suspicion of MI.16 Primary PCI is the 
default strategy for STEMI during the pandemic but thrombolysis, 
while not the preferred option, is recommended to be considered on 
an individual basis for unstable patients with COVID-19 pneumonia 
who develop STEMI.1
As with hs-cTnI, patients with COVID-19 often demonstrate 
significant elevation of BNP or NT-proBNP. The significance of this 
finding is uncertain and therefore should not necessarily trigger an 
evaluation or treatment for heart failure unless there is clear clinical 
evidence to support the diagnosis. Transthoracic echocardiography 
(TTE) is the investigation of choice in patients with COVID-19 
patients and high clinical suspicion for heart failure. BSE guidelines 
recommend that TTE requests should be approved by a cardiology 
consultant and a limited bedside study can be performed by a FIT-
tested echocardiographer with full PPE to minimise patient exposure 
and transmission of disease.
Another indication for transthoracic echocardiography is the 
development of haemodynamic instability, which may be due 
to cardiac tamponade. This could, for example, be as a result 
of haemorrhagic conversion of an underlying serous effusion. 
Transoesophageal echocardiography (TOE) is considered an aerosol-
generating procedure and hence not recommended routinely but can 
be considered in rare instances (eg infective endocarditis) following a 
multidisciplinary team discussion where surgery is contemplated. 
Research 
As our patients become involved in clinical trials investigating 
treatments for COVID-19 infection, it needs to be remembered that 
some of the potential drugs have significant cardiac side effects. 
Antiviral drugs like lopinavir and ritonavir may cause QT and PR 
prolongation, while chloroquine and hydroxychloroquine have 
the potential for myocardial toxicity and pro-arrhythmic effects 
including AV block, QT prolongation and ventricular arrhythmias. 
Summary
The key messages for non-cardiology physicians are that cardiologists 
are using alternative means of communication such as electronic 
media for essential referrals and are postponing any non-urgent 
procedures including non-urgent echocardiography and cardiac 
catheterisation. Patients with cardiovascular disease are at increased 
risk for COVID-19 and also have more severe disease and worse 
outcomes. Our health system will thus have to gear up its infrastructure 
for a higher involvement of technology in healthcare delivery.  
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